Walvax Biotechnology Co., Ltd. (300142.SZ)
CNY 10.82
(0.19%)
CNY 10.82
(0.19%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 613.96 Million CNY | -39.6% |
| 2022 | 1.09 Billion CNY | 13.63% |
| 2021 | 967.52 Million CNY | -8.3% |
| 2020 | 1.05 Billion CNY | 353.05% |
| 2019 | 232.88 Million CNY | -81.3% |
| 2018 | 1.24 Billion CNY | 963.85% |
| 2017 | -144.15 Million CNY | 10.1% |
| 2016 | -160.35 Million CNY | 82.15% |
| 2015 | -898.16 Million CNY | -800.81% |
| 2014 | 128.16 Million CNY | 3552.92% |
| 2013 | 3.5 Million CNY | -98.62% |
| 2012 | 253.89 Million CNY | 6.69% |
| 2011 | 237.97 Million CNY | 37.23% |
| 2010 | 173.41 Million CNY | 94.49% |
| 2009 | 89.16 Million CNY | 153.57% |
| 2008 | 35.16 Million CNY | 533.66% |
| 2007 | 5.54 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 112.98 Million CNY | 7.3% |
| 2024 Q3 | 97.66 Million CNY | -13.56% |
| 2024 Q1 | 105.29 Million CNY | 262.19% |
| 2023 Q2 | 417.57 Million CNY | 94.69% |
| 2023 Q1 | 214.47 Million CNY | -20.67% |
| 2023 Q3 | 147.25 Million CNY | -64.74% |
| 2023 Q4 | -64.92 Million CNY | -144.09% |
| 2023 FY | 664.07 Million CNY | -39.6% |
| 2022 FY | 1.09 Billion CNY | 13.63% |
| 2022 Q1 | 201.51 Million CNY | 37.41% |
| 2022 Q3 | 451.07 Million CNY | -13.82% |
| 2022 Q2 | 523.43 Million CNY | 159.75% |
| 2022 Q4 | 270.36 Million CNY | -40.06% |
| 2021 Q4 | 146.65 Million CNY | 50.88% |
| 2021 Q1 | 94.87 Million CNY | -87.2% |
| 2021 Q2 | 371.53 Million CNY | 291.59% |
| 2021 Q3 | 97.2 Million CNY | -73.84% |
| 2021 FY | 967.52 Million CNY | -8.3% |
| 2020 Q1 | -16.45 Million CNY | -136.15% |
| 2020 Q2 | 134.67 Million CNY | 918.31% |
| 2020 FY | 1.05 Billion CNY | 353.05% |
| 2020 Q3 | 516.9 Million CNY | 283.82% |
| 2020 Q4 | 741.15 Million CNY | 43.38% |
| 2019 Q2 | 79.64 Million CNY | 42.72% |
| 2019 FY | 232.88 Million CNY | -81.3% |
| 2019 Q1 | 55.8 Million CNY | -94.98% |
| 2019 Q3 | 51.89 Million CNY | -34.84% |
| 2019 Q4 | 45.52 Million CNY | -12.27% |
| 2018 Q1 | 31.61 Million CNY | 154.33% |
| 2018 FY | 1.24 Billion CNY | 963.85% |
| 2018 Q3 | 32.52 Million CNY | -53.68% |
| 2018 Q4 | 1.11 Billion CNY | 3316.11% |
| 2018 Q2 | 70.2 Million CNY | 122.04% |
| 2017 Q3 | -922.52 Thousand CNY | 93.12% |
| 2017 FY | -144.15 Million CNY | 10.1% |
| 2017 Q1 | -71.62 Million CNY | -153.63% |
| 2017 Q2 | -13.4 Million CNY | 81.28% |
| 2017 Q4 | -58.19 Million CNY | -6208.29% |
| 2016 Q3 | -93.88 Million CNY | 37.69% |
| 2016 FY | -160.35 Million CNY | 82.15% |
| 2016 Q1 | -49.33 Million CNY | 93.51% |
| 2016 Q4 | 133.55 Million CNY | 242.25% |
| 2016 Q2 | -150.68 Million CNY | -205.4% |
| 2015 Q2 | -27.89 Million CNY | 51.04% |
| 2015 FY | -898.16 Million CNY | -800.81% |
| 2015 Q4 | -760.66 Million CNY | -1345.4% |
| 2015 Q3 | -52.62 Million CNY | -88.67% |
| 2015 Q1 | -56.97 Million CNY | -117.77% |
| 2014 Q1 | -63.49 Million CNY | -225.92% |
| 2014 Q2 | -19.09 Million CNY | 69.92% |
| 2014 Q3 | -109.88 Million CNY | -475.35% |
| 2014 Q4 | 320.64 Million CNY | 391.8% |
| 2014 FY | 128.16 Million CNY | 3552.92% |
| 2013 Q1 | 16.5 Million CNY | -78.49% |
| 2013 Q2 | 61.7 Million CNY | 273.84% |
| 2013 Q3 | -55.21 Million CNY | -189.49% |
| 2013 Q4 | -19.48 Million CNY | 64.72% |
| 2013 FY | 3.5 Million CNY | -98.62% |
| 2012 Q2 | 95.43 Million CNY | 259.22% |
| 2012 Q1 | 26.56 Million CNY | -67.38% |
| 2012 FY | 253.89 Million CNY | 6.69% |
| 2012 Q4 | 76.74 Million CNY | 39.16% |
| 2012 Q3 | 55.14 Million CNY | -42.21% |
| 2011 Q3 | 59.78 Million CNY | -20.89% |
| 2011 Q4 | 81.44 Million CNY | 36.24% |
| 2011 Q1 | 21.17 Million CNY | -63.8% |
| 2011 FY | 237.97 Million CNY | 37.23% |
| 2011 Q2 | 75.56 Million CNY | 256.79% |
| 2010 Q2 | 52.15 Million CNY | 406.71% |
| 2010 FY | 173.41 Million CNY | 94.49% |
| 2010 Q4 | 58.5 Million CNY | 11.51% |
| 2010 Q3 | 52.46 Million CNY | 0.61% |
| 2010 Q1 | 10.29 Million CNY | 0.0% |
| 2009 FY | 89.16 Million CNY | 153.57% |
| 2008 FY | 35.16 Million CNY | 533.66% |
| 2007 FY | 5.54 Million CNY | 0.0% |